Watch out for 4 IPOs opening on August 4— here’s a snapshot for each of the companies selling shares tomorrow

Advertisement
Watch out for 4 IPOs opening on August 4— here’s a snapshot for each of the companies selling shares tomorrow
BCCL
  • The initial public offering (IPOs) of Devyani International, Exxaro Tiles, Krsnaa Diagnostics and Windlas Biotech are opening this week.
  • The IPO of these four companies will open on August 4 and close on August 6.
  • 14 more IPOs are awaiting to open their issue this month.
July saw some interesting IPOs, which got bumper listings on exchanges including Zomato, Clean Science and Technology, G R Infraprojects and Tatva Chintan Pharma Chem.

Get ready for four more initial public offerings (IPO) opening this IPO week. Devyani International, Exxaro Tiles, Krsnaa Diagnostics and Windlas Biotech are coming up with their IPO this week from August 4 to August 6.

IPOsBid start dateBid close dateAllotment dateListing date
Windlas BiotechAugust 4August 6August 11August 17
Devyani InternationalAugust 4August 6August 11August 16
Exxaro TilesAugust 4August 6August 11August 17
Krsnaa DiagnosticsAugust 4August 6August 11August 17

Let’s look into the background of companies that will start their IPOs tomorrow:
Advertisement

Devyani International

ParticularsFY21FY20FY19
Profit/loss₹-62.9 crore₹ -121 crore₹ -94.1 crore
Revenue₹ 1,198.80 crore₹ 1,535 crore₹ 1323.6 crore

Devyani International is the largest franchisee of Yum Brands in India, which operates quick service restaurant (QSR) brands such as Pizza Hut and KFC, besides its own brands.

The company may roughly raise ₹ 1,400 crore through the IPO, according to market sources. However, in the draft red herring prospectus (DRHP) filed on May 14, the company had said that it is planning to raise ₹400 crore from fresh issue of shares.
Advertisement


The company’s business is broadly classified into three verticals that includes stores of KFC, Pizza Hut and Costa Coffee operated in India. However, revenue from Pizza Hut and Costa Coffee has been falling in the last three financial years.

Exxaro Tiles


ParticularsFY21FY20FY19
Profit₹15.2 crore₹11.2 crore₹8.9 crore
Revenue₹259.8 crore₹243.9 crore₹244 crore

Exxaro Tiles is looking to raise ₹161 crore with a price band of ₹118-120 per share.
Advertisement

The company is engaged in the manufacturing and marketing activities of vitrified tiles. It manufactures double charge vitrified tiles and glazed vitrified tiles made from ceramic materials i.e. clay, quartz, and feldspar. Its product portfolio consists of more than 1000 different designs of tiles in 6 sizes. Topaz Series, Galaxy Series, and High Gloss Series are some of the well-established products of the company.

The company supplies its products to large infrastructure projects including residential, educational, commercial, hotels, hospitals, government, builders or developers, religious institutions, etc. It also exports tiles to 13 different countries across the globe including Poland, Bosnia, USA, and others.

Krsnaa Diagnostics

Advertisement
ParticularsFY21FY20FY19
Profit₹184.9 crore₹-111.9 crore₹-58 crore
Revenue₹661.5 crore₹271.3 crore₹214.3 crore

Krsnaa Diagnostics, one of the fastest-growing diagnostic chains in India, is looking to raise ₹1,213 crore at the higher end of the price band of ₹933-954 per share.

The company offers a wide range of diagnostic services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology services to public and private hospitals, medical colleges and community health centres across India.

It has an extensive network of diagnostic centres across India primarily in non-metro cities and towns. As of December 31, 2020, it operates 1,801 diagnostic centres that are offering radiology and pathology services across 13 different cities in India.
Advertisement

Windlas Biotech

ParticularsFY21FY20FY19
Profits₹15.5 crore₹16.2 crore₹63.8 crore
Revenue₹430.6 crore₹331.3 crore₹311.5 crore

Windlas Biotech is looking to raise ₹402 crore on its upper price band of ₹448-460. The company is a pharmaceutical formulations contract development and manufacturing organisation (CDMO). It provides pharmaceutical development services and large-scale manufacturing services.

The offer comprises ₹165 crore of fresh issue and offer for sale upto 51.42 lakh. Read more about the company here.
Advertisement

SEE ALSO: As Vodafone Idea shares dive 10% and more, here's a look at what analysts had to say about it prospect in recent weeks

Glenmark Life Sciences IPO: How to check allotment status, listing date and more
{{}}